Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
45.40
+0.50 (1.11%)
Sep 22, 2026, 1:44 PM EDT - Market open
Ionis Pharmaceuticals Employees
Ionis Pharmaceuticals had 1,480 employees as of June 30, 2026. The number of employees increased by 78 or 5.56% since the number was reported on December 31, 2025.
Employees
1,480
Change
78
Growth
5.56%
Revenue / Employee
$590,603
Profits / Employee
-$381,874
Market Cap
7.54B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 1,480 | 78 | 5.56% |
| Dec 31, 2025 | 1,402 | 333 | 31.15% |
| Dec 31, 2024 | 1,069 | 142 | 15.32% |
| Dec 31, 2023 | 927 | 131 | 16.46% |
| Dec 31, 2022 | 796 | 136 | 20.61% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| ImmunityBio | 691 |
| Vaxcyte | 507 |
| Rhythm Pharmaceuticals | 414 |
| TG Therapeutics | 399 |
| Immunovant | 315 |
| Praxis Precision Medicines | 168 |
| CG Oncology | 142 |
IONS News
- 5 hours ago - Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study - Reuters
- 5 hours ago - Ionis announces Phase 3 FUSION study of ulefnersen met primary endpoint - TheFly
- 5 hours ago - Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment - Business Wire
- 5 hours ago - Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS - Business Wire
- 6 hours ago - Ionis Pharmaceuticals price target lowered to $70 from $76 at JPMorgan - TheFly
- 17 hours ago - Cathie Wood’s ARK Investment buys 100K shares of Ionis Pharmaceuticals today - TheFly
- 6 days ago - Ionis Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 7 days ago - Ionis Pharmaceuticals price target lowered to $80 from $89 at Guggenheim - TheFly